Dapsone for autoimmune thrombocytopenic purpura
β Scribed by Bertrand Godeau; Eric Oksenhendler; Philippe Bierling
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 209 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
β¦ Synopsis
Twenty-one human immunodeficiency virus (HIV)-free and six HIV-infected adults with autoimmune thrombocytopenic purpura (AITP) were treated with dapsone (100 mg/day). A response was observed in 13 patients (median platelet count before 25 x 109/L, range 3-49; after 109 x 10g/L, range 69-241). Thrombocytopenia recurred in four of the responders in whom dapsone was discontinued. No response was observed in 12 patients. Dapsone had to be withdrawn after two weeks of treatment in the remaining two patients and after six to eight weeks in three other patients due to intolerance. No serious hematological complications were observed. These results confirm that dapsone is a safe, inexpensive, and effective treatment of AITP.
π SIMILAR VOLUMES
## Abstract We report the case of a 51βyearβold male who underwent coronary stent placement for the treatment of an acute myocardial infarction. One week later, he developed symptomatic autoimmune thrombocytopenia likely related to clopidogrel use. This was successfully treated with intravenous met
levels were not different from normal subjects statistically (Table ). No significant correlations were noted between the platelet counts and serum cytokine concentrations.
Dapsone provides an alternative treatment for patients with chronic autoimmune thrombocytopenic purpura (AITP) who had inadequate response to conventional therapy. However, the efficacy of this treatment is achieved in only 50% of patients. Dapsone is partly metabolized by the polymorphic N-acetyltr